PetVivo Holdings Inc (OTCQX: PETV) reported a narrowed net loss per share of $(0.05) for the fiscal first quarter ended June 30, 2026, compared to $(0.10) in the corresponding period of the previous year. This represents a 50% improvement in losses on a per-share basis. The veterinary biomedicals provider also logged revenue of $337,572, up from $297,500 year-over-year, marking a 13.47% increase.

The company announced the acquisition of PiezoBioMembrane (PBM), an R&D partner specializing in functional biomaterials and piezoelectric technologies. Management stated the deal is subject to customary closing conditions and financing completion. PetVivo plans to pursue FDA clearance for human applications incorporating PBM’s technologies after completing safety and efficacy studies.

Financial Performance

The operating loss contracted to $1.61 million from $1.84 million in the prior year quarter. Gross profit expanded to $223,317 from $186,726, driven by higher revenues against relatively stable cost of sales which rose slightly to $114,255 from $110,774.

Total operating expenses fell to $1.83 million from $2.03 million. This reduction was primarily due to lower general and administrative expenses ($967,442 vs $1.07 million) and research and development costs ($233,419 vs $340,513). Sales and marketing expenses saw a marginal increase to $631,305 from $621,712.

Other income and expense improved significantly. The current quarter recorded only $5,039 in interest expense, whereas the prior year period included a $320,404 unrealized loss on derivative liabilities and a $149,125 loss on disposal of assets. These non-recurring items contributed to the wider net loss in the comparative period.

What the Numbers Show

The improvement in the bottom line was largely non-operational. While operating losses narrowed modestly by approximately $235,000, the year-over-year reduction in net loss is heavily influenced by the absence of significant derivative and asset disposal losses that weighed on results in the prior year. Operational efficiency gains are visible in the contraction of R&D and G&A expenses despite revenue growth.

Balance Sheet Position

Cash and cash equivalents declined to $122,633 as of June 30, 2026, from $200,782 at the end of the previous fiscal year. Total current assets stood at $941,019, down from $1.71 million, largely due to the settlement of subscriptions receivable which dropped to zero from $600,000. Inventory decreased to $451,334 from $538,366.

Total liabilities remained relatively stable at $1.31 million, with accounts payable decreasing to $453,291 from $547,421. However, notes payable and accrued interest (current portion) increased to $476,456 from $321,447. Stockholders’ equity declined to $1.36 million from $2.20 million, reflecting the accumulated deficit widening to $103.05 million.

Operational Updates

PetVivo continued the beta launch of its PetVivo.ai veterinary practice platform, claiming a 50%-90% reduction in customer acquisition costs for participating clinics. The company also advanced Stage B of its R&D program with PBM, focusing on scalable production of combined offerings for tissue regeneration. Additionally, PetVivo concluded its commercial partnership with VetStem regarding the PrecisePRP product line to focus exclusively on proprietary technologies.

PetVivo Holdings, Inc. (OTCQX: PETV) will hold a conference call on Friday, August 14, 2026, at 5:00 p.m. Eastern time to discuss financial results for the fiscal first quarter ended June 30, 2026. The Minneapolis-based biomedical company, which focuses on medical devices and therapeutics for equines and companion animals, stated that the financial results will be issued in a press release prior to the call. This disclosure ensures investors have access to the key performance metrics before the management team provides context and answers questions during the live event.

The conference call is scheduled for Friday, August 14, 2026, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). PetVivo management will host the presentation, followed by a question-and-answer period. The company has provided specific dial-in details for participants who wish to join the audio portion of the call.

Investors unable to attend via phone can access the webcast live or view the replay through the link provided by the company. A replay of the webcast will also be available via a link in the Investors section of the company’s website at petvivo.com/investors following the conclusion of the call. This multi-channel approach aims to maximize accessibility for shareholders and analysts monitoring the emerging biomedical firm.

PetVivo Holdings, Inc., operating through wholly-owned subsidiaries PetVivo Animal Health, Inc., Cosmeta Corp, and PetVivo AI, Inc., is currently focused on the manufacturing, commercialization, and licensing of innovative medical devices. The company’s strategy leverages human therapies for companion animals, aiming for accelerated timelines to revenue compared to more stringently regulated pharmaceuticals. Its lead product, SPRYNG with OsteoCushion technology, an intra-articular injection for joint-related afflictions in cats, dogs, and horses, remains available for commercial sale.

The company noted that its portfolio includes twelve patents and six trade secrets protecting its biomaterials, products, production processes, and methods of use. Forward-looking statements regarding development and commercial timelines are subject to risks detailed in the Annual Report on Form 10-K for the year ended March 31, 2026. The company disclaims any obligation to update these statements based on new information or future events.